The Pfizer men B shot grabs an approval-speeding designation just two months after GSK's Bexsero—Trumenba's archrival—got the same boost.

Thanks to widely used egg-based manufacturing, this fall's flu vaccine will be only 20% effective against the dominant strain, according to a study.

Here is some other vaccine news of note for the week.

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

Merck's Gardasil 9 has been on an upward trajectory, but high global demand for the HPV shot has created a shortage for U.K. private clinics.

At €350 million, Sanofi's new Canadian vaccine plant will be one of the largest investments ever by the company in a single facility.

The FDA is evaluating the possibility of prosecuting those involved in rogue herpes vaccine research led by a Southern Illinois University professor.